Harvard Bioscience Inc (HBIO) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.066x

Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has a cash flow conversion efficiency ratio of -0.066x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-662.00K) by net assets ($10.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Harvard Bioscience Inc to measure how many days the company can operate on defensive assets alone.

Harvard Bioscience Inc - Cash Flow Conversion Efficiency Trend (1999–2025)

This chart illustrates how Harvard Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Harvard Bioscience Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Harvard Bioscience Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Advance NanoTek Limited
F:BBJ
0.047x
Seoyon Topmetal Co. Ltd
KQ:019770
-0.023x
Garda Tujuh Buana Tbk
JK:GTBO
-0.014x
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
-0.336x
Verde Agritech PLC
TO:NPK
0.062x
Nova MSC Bhd
KLSE:0026
-0.084x
Jembo Cable Company Tbk
JK:JECC
-0.109x
Fun Yours Technology Co Ltd
TWO:6482
0.043x

Annual Cash Flow Conversion Efficiency for Harvard Bioscience Inc (1999–2025)

The table below shows the annual cash flow conversion efficiency of Harvard Bioscience Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see HBIO company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $13.73 Million $6.73 Million 0.490x +2055.11%
2024-12-31 $63.34 Million $1.44 Million 0.023x -88.16%
2023-12-31 $73.07 Million $14.03 Million 0.192x +1103.48%
2022-12-31 $72.22 Million $1.15 Million 0.016x +5.42%
2021-12-31 $83.40 Million $1.26 Million 0.015x -87.56%
2020-12-31 $76.68 Million $9.33 Million 0.122x +23.54%
2019-12-31 $81.69 Million $8.05 Million 0.099x +245.36%
2018-12-31 $82.18 Million $2.34 Million 0.029x +118.30%
2017-12-31 $80.90 Million $1.06 Million 0.013x -82.48%
2016-12-31 $72.20 Million $5.38 Million 0.075x +720.68%
2015-12-31 $77.60 Million $705.00K 0.009x -80.07%
2014-12-31 $95.47 Million $4.35 Million 0.046x +6.06%
2013-12-31 $94.48 Million $4.06 Million 0.043x -44.46%
2012-12-31 $104.21 Million $8.06 Million 0.077x +16.38%
2011-12-31 $95.50 Million $6.35 Million 0.066x -51.20%
2010-12-31 $90.25 Million $12.29 Million 0.136x -37.91%
2009-12-31 $75.26 Million $16.51 Million 0.219x +59.05%
2008-12-31 $66.72 Million $9.20 Million 0.138x -15.18%
2007-12-31 $74.14 Million $12.05 Million 0.163x +39.88%
2006-12-31 $71.88 Million $8.36 Million 0.116x +53.09%
2005-12-31 $68.42 Million $5.20 Million 0.076x -30.72%
2004-12-31 $104.36 Million $11.44 Million 0.110x +434.44%
2003-12-31 $98.88 Million $2.03 Million 0.021x +126.72%
2002-12-31 $88.38 Million $799.46K 0.009x -85.24%
2001-12-31 $66.81 Million $4.10 Million 0.061x +49.49%
2000-12-31 $52.33 Million $2.15 Million 0.041x -88.81%
1999-12-31 $7.98 Million $2.93 Million 0.367x --

About Harvard Bioscience Inc

NASDAQ:HBIO USA Medical Instruments & Supplies
Market Cap
$27.06 Million
Market Cap Rank
#24164 Global
#5137 in USA
Share Price
$6.00
Change (1 day)
+0.84%
52-Week Range
$0.38 - $7.24
All Time High
$8.47
About

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more